Aileron provides Lung Therapeutics financials: net loss $19M in 2022, accumulated deficit $63M, going concern cited

Rein Therapeutics, Inc.

Lung Therapeutics net loss $19.0M in 2022, $9.9M in 2021; cash and equivalents $11.9M at Dec 31, 2022.
Accumulated deficit $63.4M; auditor's report includes substantial doubt about going concern.
Lung's lead candidate LTI-03 (IPF) in Phase 1b; LTI-01 (LPE) completed Phase 2.
Pro forma condensed combined financial statements also filed with this 8-K/A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.